User:MeirBialer/sandbox/Meir Bialer

= Professor Meir Bialer, PhD, MBA = Meir Bialer, PhD, MBA, is the David H. Eisenberg Emeritus (active) Professor of Pharmacy at the School of Pharmacy, Faculty of Medicine of the Hebrew University of Jerusalem. He received his B. Pharm (with distinction, 1969), M.Sc. (with distinction, 1971), M.B.A (1976). and Ph.D. (1977) degrees from The Hebrew University of Jerusalem. Dr. Bialer completed a postdoctoral fellowship in pharmacokinetics at the University of Florida and spent an additional year at the College of Pharmacy at the University of Kentucky. Since 1980 he has been a member of the faculty of the School of Pharmacy and Faculty of Medicine of the Hebrew University of Jerusalem. From 1994-1997 he served as Head of the Department of Pharmaceutics in the School of Pharmacy. Professor Bialer has been awarded the Fellow (1992) of the American Association of Pharmaceutical Scientists (AAPS), Kaye Innovation Award of the Hebrew University of Jerusalem (2000, 2007 & 2008), an Ambassador for Epilepsy Award (2001) of The International League Against Epilepsy (ILAE) and The International Bureau for Epilepsy (IBE). Between 2009 and 2017 Professor Bialer was the Chair of the ILAE-Commission on European Affairs (ILAE-Europe or CEA). He is also the co-founder and member of the Organizing Committees of the sixteen (1992-2022) EILAT Conferences on New Antiepileptic Drugs and Devices, the eight Eilat International Educational Courses on the Pharmacological Treatment of Epilepsy (2005-2019) and the four (1988-1999) Jerusalem Conferences on Pharmaceutical Sciences and Clinical Pharmacology. He is a former president of the Israeli Society of Clinical Pharmacy and Biopharmaceutics (1989-1999) and of the Israeli League Against Epilepsy (1996-2002). He has served or is currently serving as a member of the editorial board of the following international journals: Biopharmaceutics & Drug Disposition (1988-2012), CNS Drugs (1994-present), Epilepsia (2000-2010), Epilepsy & Behaviour (2002-present), Epilepsy Research (2007-present), European Journal of Pharmaceutical Sciences (1992-1998), Journal of Pharmaceutical Sciences (1990-1995) and Therapeutic Drug Monitoring (1999-present).

He has devoted much time and energy to assisting the ILAE, and his work has included:


 * Chair (2009-2017) of the Commission on European Affairs (ILAE-Europe or CEA) or ILAE-Europe and previously treasurer (2001-2009).
 * Membership of various ILAE commissions, including ILAE-Europe, the subcommission on therapeutic drug monitoring of antiepileptic drugs (AEDs) and the task force on regulatory affairs of AEDs.
 * Member of the Scientific and Organizing Committees of several European Congresses on Epileptology, Co-Chair of the scientific and organizing committee of the Berlin (2008), London (2012), Stockholm (2014), Prague (2016) and Vienna (2018) congresses, respectively.

Prof. Bialer’s research interests include: a) Pharmacokinetics of new antiepileptic drugs (AEDs) and pharmacokinetic-based design of new antiepileptics and CNS drugs. In this regard he has been utilizing structure pharmacokinetic pharmacodynamic relationship (SPPR) studies to deign and develop new CNS drugs with better potency, lack of teratogenicity and a wide safety margin; b) Pharmacokinetic analysis of new drugs, sustained release dosage forms and novel drug delivery systems (DDS); c) Stereospecific pharmacokinetic and pharmacodynamic analysis of chiral drugs; d) Pharmacogenetics of CNS drugs; and e) Pharmacoresistance to AEDs. In these areas, he has 259 peer reviewed publications and is an author of 16 book chapters.

Personal Information:
Date and place of birth:    January 30, 1948; Petach Tikva, Israel

Citizenship:                       Israeli

Army service:                    1971-1973

Marital status:                   Married, two children, five grandchildren

Academic Education:
1965-1969           School of Pharmacy, Hebrew University of Jerusalem, Israel. Received Bachelor of Pharmacy (B.Pharm.) "with distinction."

1969-1971           School of Pharmacy, Hebrew University of Jerusalem, Israel. Received M.Sc."with distinction" in Medicinal Chemistry. M.Sc. Dissertation: "Degradation and Cleavage of Δ14-17-Keto Steroids."

1972-1975           School of Business Administration, Hebrew University of Jerusalem, Israel. Received M.A. in Business Administration. Special emphasis on finance.

1973-1977           School of Pharmacy, Hebrew University of Jerusalem, Israel. Received Ph.D. in Medicinal Chemistry. Ph.D. dissertation: "Antiviral Structure - Activity Relationship of Distamycin and its Derivatives."

Academic Career:
1969-1971         Teaching and Research Assistant, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.

1973-1977         Assistant and Instructor, School of Pharmacy, The Hebrew University of Jerusalem, Israel.

1980-1984         Lecturer, Department of Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. Research fields: pharmacokinetics, biopharmaceutics and antiepileptic drugs.

1984-1988         Senior Lecturer, Department of Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem.

1985-Present     First incumbent, David H. Eisenberg Chair in Pharmacy.

1988-1993          Associate Professor and David H. Eisenberg Professor of Pharmacy, Department of Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem.

1993-Present     Full Professor, Department of Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem.

1994-1997          Head of the Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem

Research and Professional Experience:
1977-1979          Post-Doctorate Fellow at College of Pharmacy, University of Florida, Gainesville, Florida, USA. Special emphasis on pharmacokinetics. Major project: Pharmacokinetics of a cardiovascular drug, Bretylium, in humans.

1979-1980          Post-Doctorate Fellow at College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA. Special emphasis on pharmacokinetics and biopharmaceutics.

1982 (summer)   Visiting Scientist (award of the British Royal Society) at the Department of Pharmacy, University of Manchester, England. Specialized in interspecies animal scaling and data analysis in pharmacokinetics.

1983 (summer)   Visiting Scientist at the Hvidivre Hospital, University Copenhagen, Department of Neurology, Denmark and the Norwegian National Center for Epilepsy, Sandvika, Norway.

1983 (fall)           Visiting Scientist at the Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.

1984-1985          Sabbatical leave. Consultant and Visiting Scientist, Pharmacodynamics Department, Lederle Laboratories, Pearl River, New York, USA.

1989 & 1990 (summer) Consultant and Visiting Scientist, Biopharmaceutics and Pharmaco- kinetic Div., Schering-Plough Research, Pembroke Pines, FL, USA.

1991, 1992 &      Consultant and Visiting Professor, Department of Pharmacokinetics

1993 (summer)   and Drug Metabolism, Schering-Plough Research, New Jersey, USA.

1994 (summer)   Consultant and Visiting Professor, CNS Discovery group, Alza Pharmaceuticals, Palo Alto, California, USA.

1997 (winter)      Visiting Professor on sabbatical, University of Otago, School of Pharmacy, Dunedin, New Zealand.

1997 (spring-summer)      Consultant and Visiting Professor on sabbatical, Taro Research Pharmaceuticals Institute, New York, USA.

1998 (summer)   Consultant and Visiting Professor, Clinical Pharmacology Division, Wyeth Ayerst, Radnor, Pennsylvania, USA.

1999 (summer)   Consultant and Visiting Professor, Neuroscience Drug Discovery,

Bristol Myers Squibb, Wallingford, Connecticut, USA.

2001 (winter)      A William Evans Visiting Professor on sabbatical, School of Pharmacy, University of Otago, Dunedin, New Zealand.

2001 (spring-summer) Consultant and Visiting Professor on sabbatical, The R.W. Johnson Pharmaceutical Research Institute (PRI), Raritan, New Jersey, USA.

Teaching Experience:

 * 1) Lecturer in and responsible for the courses:
 * 2) Pharmacokinetics and Biopharmaceutics (56 hours).
 * 3) Advanced Pharmacokinetics – given to PhD and MSc students (42 hours)
 * 4) Biostatistics in Pharmaceutical Sciences– given to PhD and MSc students (42 hours)
 * 5) Outstanding Lecturer Award, School of Pharmacy, Faculty of Medicine, The Hebrew
 * 6) University of Jerusalem - 1983, 1986, 1987, 1988, 1989, 1991, 1993.

Research Supervision:
Thirty one Ph.D. students since 1981: three jointly with Prof. Michael Friedman - Joseph Dubrovsky (1981-1984), Abraham Rubinstein (1981-1985) and Ziad Hussein (1983-1986); ten jointly with Prof. Boris Yagen - Amnon Sintov (1983-1986), Shimon Barel (1987-1993), Ofer Spiegelstein (1995-1999), Nina Isoherranen (1998-2002), Eyal Sobol (2001-2006), Sara Eyal (2001-2006), Jakob Shimshoni (2002-2008), Dan Kaufman (2002-2009), Neta Pessah (2004-2010) and Naama Hen (2007-2013); one jointly with Prof. Raphael Mechoulam - Emil Samara (1984-1989), five as the sole supervisor - Abdullah Haj-Yehia (1986-1991), Salim Hadad (1987-1993), Ilan Winkler (2000-2005), Hafiz Mawasi (2012-2016) and David Bibi (2015-2020), four jointly with Yossef  Caraco - Liat Adar (2000-2008), Idit Ashash (2005-2011), Hanan Shaul (2014-2019) and Maor Wanounou (2021) one jointly with Felix Bergman - Simcha Blotnik (1990-1997); three jointly with Dr. Stephan Soback - Marina Gips (1990-1995), Malka Britzi (2000-2006) and Dorit Mimrod (2002-2008);  one jointly with Arie Dagan - Sherbel Sussan (1992-1998); one jointly with Boris Yagen and Amnon Sintov - Andrew Volosov (1995-2000),  one jointly with Eylon Yavin - Tawfeeq Shekh-Ahmad (2010-2014) and one jointly with Sara Eyal- Natalia Erenburg (2019).

President of:
Twenty-one M.Sc. students since 1981: Ziad Hussein (1981-1983), Emil Samara (1982-1984), Karbush Salame (1982-1984), Zahrura Pharj (1984-1986), Hanna Rozin-Billig (1986-1989), Khalil Badir (1987-1990), Ali Abdel Hai (1989-1991), Yossi Lomnizki (1988-1993), Omar Abu Salach (1990-1994), Bashier Kadry (1995-1997), Sergey Rozenshtrakh (2002-2005), David Bibi (2014-2015), Suail Zahada (2015-2017), and Reem Odi (2019-2021). Three jointly with Prof. Boris Yagen - Micha Levi (1994-1996), Niv Papo (1997-1999) and Matvey Wasserman (1999-2001), one jointly with Dr. Stefan Soback and Prof. Jaime Kapitulnik - Malka Britzi (1994-1998), one jointly with Prof. Yossi Caraco- Amit Alankry (2004-2007) one jointly with Dr. Eylon Yavin - Tawfeeq Shekh-Ahmad (2009-2010) and two jointly with Sara Eyal - Bella Shusterman (2017-2020) and Natalia Erenburg (2018)

President of:

 * Israel League Against Epilepsy, a branch of the International League Against Epilepsy (ILAE), 1996-2001, and its secretary 2002-present
 * Israel Society of Clinical Pharmacy and Biopharmaceutics (ISCPB), a member of the European Society of Pharmaceutical Sciences (EUFEPS) 1991-2001

Cofounder and Member of the Organizing Committee of:

 * The SIXtheen Eilat Conferences on New Antiepileptic Drugs (1992, 1994, 1996, 1998, 2000, 2002, 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018, 2020 and  2022)
 * The eight Eilat International Educational Courses on the Pharmacological Treatment of Epilepsy (2005, 2007, 2009, 2011, 2013, 2015, 2017 and 2019).
 * The four Jerusalem Conferences on Pharmaceutical Sciences and Clinical Pharmacology (1988, 1992, 1996 and 1999)

Awards

 * A Fellow of the American Association of Pharmaceutical Sciences - AAPS (1992)
 * Kaye Innovation Awards at The Hebrew University of Jerusalem (2000, 2006       and 2007)
 * Ambassador for Epilepsy Award of The International League Against Epilepsy - ILLAE and The International Bureau for Epilepsy – IBE (2001)
 * An expert member of the Board of Pharmaceutical Sciences (BPS) of the FIP-Federation International Pharmaceutique (2001-2005)
 * Honorary member of the All Russian Society of Neurologists (2012)
 * Honorary member of the German League against Epilepsy (2014)
 * Honorary member and a Special Award of the Georgian League against Epilepsy (2017)

Member of the Editorial Boards of:

 * Biopharmaceutics and Drug Disposition (1988-2010)
 * CNS Drugs (1994- present)
 * Epilepsia (2000-2009)
 * Epilepsy and Behavior (2002- present)
 * Epilepsy Research (2007- present)
 * European Journal of Pharmaceutical Sciences (1993-1998).
 * Journal of Pharmaceutical Sciences (1990-1995)
 * Therapeutic Drug Monitoring (1999- present)

List of Publications

 * 1) M. Bialer: Antiviral SAR of distamycin A and its derivatives. Ph.D. dissertation, Hebrew University of Jerusalem (1977).
 * 2) M. Bialer, B. Yagen and R. Mechoulam: A total synthesis of distamycin A, an antiviral antibiotic. Tetrahedron 34:2389-2391 (1978).
 * 3) M. Bialer, B. Yagen, R. Mechoulam and Y. Becker: Structure-activity relationship of pyrrole amidine antiviral antibiotics. 1. Modifications of the alkylamidine side chain. J. Med. Chem. 21:1296-1301 (1979).
 * 4) M. Bialer, S.D. Sloneker and H.B. Kostenbauder: Identification of and inhibitor of pulmonary biotransformation in tobacco smoke condensate. Proceedings of the Fifth Workshop Conference. (S.L. Sullivan, Ed.) Published by the Tobacco and Health Research Institute, Lexington, Kentucky, pp. 158-172 (1979).
 * 5) M. Bialer: A simple method for determining whether absorption and elimination rate constants equal in the one compartment body model with first order processes. J. Pharmacokinet. Biopharm. 8:111-113 (1980).
 * 6) M. Bialer, B. Yagen, R. Mechoulam and Y. Becker: Structure-activity relationships of pyrrole amidine antiviral antibiotics. 2. Preparation of mono- and tri-pyrrole derivatives of congocidine. J. Med. Chem. 23:1144-1148 (1980).
 * 7) M. Bialer, B. Yagen, R. Mechoulam and Y. Becker: Structure-activity relationships of pyrrole amidine antiviral antibiotics III: Preparation of distamycin and congocidine derivatives based on 2,5-disubstituted pyrroles. J. Pharm. Sci. 69:1134-1138 (1980).
 * 8) M. Bialer, B. Yagen and R. Mechoulam: Structure elucidation of a novel condensation product of 4-aminopyrrole derivative and dicyclohexylcarbodiimide. J. Heter. Chem.17:1797-1798 (1980).
 * 9) M. Bialer, J. El-On, B. Yagen and R. Mechoulam: Antiparasitic structure-activity relationships of congocidine derivatives. J. Pharm. Sci. 70:822-824 (1981).
 * 10) M. Bialer: An alternative method for calculating simple pharmacokinetic parameters for zero-order absorption and first-order elimination processes. Biopharm. Drug Disposit. 2:323-327 (1981).
 * 11) D.W.A. Bourne, M. Bialer, L.W. Dittert, M. Hayashi, G. Rudawsky, G.D. Koritz and R.F. Bevill: Disposition of sulfadimethoxide in cattle: Inclusion of protein binding parameters in a pharmacokinetic model. J. Pharm. Sci. 70:1068-1072 (1981).
 * 12) M. Bialer: An unusual cleavage of ring D in a Δ14-17-keto steroid after a reaction with alkaline hydrogen peroxide. Tetrahedron Lett. 22:2683-2684 (1981).
 * 13) M. Bialer, B. Yagen, R. Mechoulam, Y. Becker and J. El-On: Antiparasitic and antiviral activity of congocidine and distamycin A derivatives. In: Current Chemotherapy and Immunotherapy. (P.Periti and G.G. Grassi, Eds.) American Society for Microbiology, Washington, D.C., U.S.A., pp. 1048-1050 (1982).
 * 14) E.R. Garrett, J.R. Green and M. Bialer: Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. Biopharm. Drug Disposit. 3:129-164 (1982).
 * 15) M. Bialer: Estimation of pharmacokinetic parameters in extravascular multiple dose administration in the one compartment open body model with equal absorption and elimination rate constants. Int. J. Pharm. 13:345-348 (1983).
 * 16) M. Bialer and A. Rubinstein: A comparative study on the pharmacokinetics of valpromide after i.v. administration in dogs. J. Pharm. Pharmacol. 38:607-609 (1983).
 * 17) M. Bialer, Z. Hussein, Y. Herishanu and Y. Melnik: An alternative method for calculating absorption and elimination rate constants in first order processes: application to valproic acid. Int. J. Pharm. 16:285-294 (1983).
 * 18) M. Bialer: Distamycin and its derivatives. In: Antiviral Drugs and Interferon. The   Molecular Basis of Their Activity. (Y. Becker, Ed.), Mortonus Nijhoff Pub., Mass., U.S.A., pp. 143-156 (1984).
 * 19) M. Bialer, M. Friedman and J. Dubrovsky: Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. Biopharm. Drug Disposit. 5:1-10 (1984).
 * 20) M. Bialer, Z. Hussein, J. Dubrovsky, I. Raz and O. Abramsky: Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Isr. J. Med. Sci. 20:46-50 (1984).
 * 21) M. Bialer, M. Friedman, A. Rubinstein and J. Dubrovsky: Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid, and i.v. preparation of valpromide in dogs. In: Metabolism of Antiepileptic Drugs. (R.H. Levy, W.H. Pitlick, M. Eichelbaum and J. Meijer, Eds.), Raven Press, New York, U.S.A., pp. 143-153 (1984).
 * 22) M. Bialer and A. Rubinstein: Pharmacokinetics of valpromide in dogs after various routes of administration. Biopharm. Drug Disposit. 5:177-185 (1984).
 * 23) M. Bialer, M. Friedman and A. Rubinstein: A rapid GLC assay for monitoring valproic acid and valpromide in plasma. J. Pharm. Sci. 73:991-993 (1984).
 * 24) M. Bialer, M. Friedman and J. Dubrovsky: Effect of sustained-release on the pharmacokinetics of valproic acid in dog. Int. J. Pharm. 20:53-63 (1984).
 * 25) I. Raz, M. Bialer, K. Salame and H. Bar-On: Comparative pharmacokinetic analysis of a sustained release dosage form of theophylline in humans. Eur. J. Clin. Pharmacol. 26:401-403 (1984).
 * 26) M. Bialer, S.D. Sloneker and H.B. Kostenbauder: Isolation of a tobacco smoke fraction responsible for the inhibition of benzo(a)pyrene metabolism in the isolated perfused rabbit lung. Chem. Biol. Inter. 51:309-320 (1984).
 * 27) I. Juno, M. Bialer, S.A. Nickelson and R.H. Levy: Disposition of progabide and valproic acid following intraperitoneal administration in Rhesus monkey. Epilepsia 25:578-585 (1984).
 * 28) M. Bialer, A. Rubinstein, I. Raz and O. Abramsky: Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur. J. Clin. Pharmacol. 27:501-503 (1984).
 * 29) M. Bialer and B. Hoch: Rapid gas chromatographic assay for monitoring valnoctamide in plasma. J. Chromatog. Biomed. Appl. 337:408-411 (1985).
 * 30) M. Bialer, Z. Hussein, I. Raz, O. Abramsky, Y. Herishnau and F. Pachys: Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharm. Drug Disposit. 6:33-42 (1985).
 * 31) M. Bialer, A. Rubinstein, J. Dubrovsky, I. Raz and O. Abramsky: A comparative   pharmacokinetic study of valpromide and valproic acid after i.v. administration to   humans. Int. J. Pharm. 23:25-33 (1985).
 * 32) B. Yagen, M. Bialer and A. Sintov: A gas chromatographic assay with phramacokinetic applications for monitoring T-2 toxin and HT-2 toxins in plasma.  J. Chromatog. Biomed. Appl. 343:67-75 (1985).
 * 33) M. Bialer, M. Friedman, J. Dubrovsky, I. Raz and O. Abramsky: Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. Biopharm. Drug Disposit. 6:401-411 (1985).
 * 34) M. Bialer, K. Salame and I. Raz: Effect of sustained release on the pharmacokinetics of theophylline in healthy subjects. Int. J. Clin. Pharmacol. Ther. Toxicol. 23:662-667 (1985).
 * 35) A.P. Tonelli, M. Bialer and A. Yacobi: Relationship between protein binding and renal clearance of a new oral cephalosporin in the dog. J. Pharm. Sci. 74:1242-1244 (1985).
 * 36) M. Bialer, A.P. Tonelli, J.P. Kantrowitz and A. Yacobi: Serum protein binding of a new oral cephalosporin, CL 284, 635, in various species. Drug Metab. Disposit. 14:132-136 (1986).
 * 37) B. Yagen, A. Sintov and M. Bialer: A new sensitive TLC/HPLC method for detection of trichothecene mycotoxins using dis-chloride reagent. J. Chromatog. 356:195-201 (1986).
 * 38) Y.Y. Pei, M. Bialer and R.H. Levy: Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat. Biopharm. Drug Disposit. 7:11-19 (1986).
 * 39) A. Sintov, M. Bialer and B. Yagen: Pharmacokinetics of T-2 toxin and its metabolite HT-2 toxin, after intravenous administration in dogs. Drug Metab. Disposit. 14:250-254 (1986).
 * 40) M. Bialer, M. Friedman and J. Dubrovsky: Relation between absorption half-life values of four novel sustained-release dosage forms of valproic acid in dogs and humans. Biopharm. Drug Disposit. 7:495-500 (1986).
 * 41) A. Rubinstein, M. Bialer, M. Friedman, I. Raz and O. Abramsky: A combined approach to control valproic acid release via novel drug delivery systems of valpromide: A kinetic and pharmacokinetic study. J. Control. Release 4:33-38 (1986).
 * 42) A.P. Tonelli, M. Bialer, Z.M. Look, S. Carson and A. Yacobi: Saturable processes affecting renal clearance of cefixime in dogs. Pharm. Res. 3:150-155 (1986).
 * 43) M. Bialer, Z.M. Look, B.M. Silber and A. Yacobi: The relationship between drug input and mean residence time in the body. Biopharm. Drug Disposit. 7:577-583 (1986).
 * 44) B.M. Silber, M. Bialer and A. Yacobi: Pharmacokinetic/pharmacodynamic basis of controlled drug delivery. In: Controlled Drug Delivery. (J.R. Robinson and V.H. Lee, Eds.), 2nd Edition, Marcel Dekker, New York, U.S.A., pp. 213-252 (1987).
 * 45) M. Bialer, V.K. Batra, J. Morrison, B.M. Silber and A. Yacobi: Dose dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog. Pharm. Res. 4:33-37 (1987).
 * 46) Z. Hussein, M. Bialer, M. Friedman and I. Raz: A comparative pharmacokinetic evaluation of theophylline sustained release formulations in dogs and humans. Int. J. Pharm. 37:97-102 (1987).
 * 47) M. Bialer, W.H. Wu, Z.M. Look, B.M. Silber and A. Yacobi: Pharmacokinetics of cefixime after oral and intravenous doses in dog: Bioavailability assessment for a drug showing nonlinear serum protein binding. Res. Comm. Clin. Pharmacol. Ther. 56:21-32 (1987).
 * 48) E. Samara and M. Bialer: A rapid HPLC assay for the pharmacokinetics applications for monitoring cannabidiol in plasma. J. Chromatog. Biomed. Appl. 416:370-374 (1987).
 * 49) A. Sintov, M. Bialer and B. Yagen: Pharmacokinetics of T-2 tetraol, a urinary metabolite of T-2 toxin in dog. Xenobiotica. 17:941-950 (1987).
 * 50) Z. Hussein, M. Bialer, M. Friedman and I. Raz: Pharmacokinetic analysis of sustained release dosage forms of theophylline in humans: Comparison of single and multiple dose studies. Biopharm. Drug Disposit. 8:427-435 (1987).
 * 51) M. Bialer, S.A. Kaplan and A. Yacobi: Animal models in the primary screening of controlled-release formulations. In: Oral Sustained-Release Formulations. (A. Yacobi, and E. Halperin-Walega, Eds.), Pergamon Press, New York, U.S.A. (1988) pp. 183-193.
 * 52) A. Sintov, M. Bialer and B. Yagen: Pharmacokinetics and protein binding of trichothecene mycotoxins, T-2 toxin and HT-2 toxin in dogs. Toxicon. 26:153-160 (1988).
 * 53) M. Bialer, W.H. Hu, R.D. Faulkner, B.M. Silber and A. Yacobi: In vitro protein binding interaction studies involving cefixime. Biopharm. Drug Disposit. 9:315-320 (1988).
 * 54) E. Samara, M. Bialer and R. Mechoulam: Pharmacokinetics of cannabidiol in dogs. Drug Metab. Disposit. 16:469-472 (1988).
 * 55) M. Maislos, M. Bialer, P.M. Mead and D. Robbins: Pharmacokinetic model for circulating covalent aggregates of insulin. Diabetes. 37:1059-1063 (1988).
 * 56) E. Samara and M. Bialer: Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs. Drug Metab. Disposit. 16:875-879 (1988).
 * 57) A. Haj-Yehia and M. Bialer: Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J. Pharm. Sci. 77:831-834 (1988).
 * 58) J. Ben-David and M. Bialer: Pharmacokinetic interaction between diltiazem and amiodarone in the dog. Biopharm. Drug Disposit. 10:423-429 (1989).
 * 59) E.J. Mason and M. Bialer: The logical structure and validity of experimental design in pharmacokinetics and clinical pharmacology. Biopharm. Drug Disposit. 10:331-334 (1989).
 * 60) A. Haj-Yehia and M. Bialer: Structure-pharmacokinetic relationships in a series of valpromide isomers with antiepileptic activity. Pharm. Res. 6:683-689 (1989).
 * 61) H. Billig, E. Ziv, H. Bar-On and M. Bialer: The disposition of valpromide in rats and the isolated perfused rat liver. Drug Metab. Disposit. 18:238-244 (1990).
 * 62) S. Barel, B. Yagen and M. Bialer: Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs. J. Pharm. Sci. 79:548-551 (1990).
 * 63) M. Bialer, A. Haj-Yehia, N. Barzaghi, F. Pisani and E. Perucca: Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur. J. Clin. Pharmacol. 38:289-291 (1990).
 * 64) A. Haj-Yehia and M. Bialer: Structure pharmacokinetic relationships in series of short fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 79:719-724 (1990).
 * 65) E. Samara, M. Bialer and D.J. Harvey: Identification of urinary metabolites of cannabidiol in the dog. Drug Metab. Disposit. 18:571-579 (1990).
 * 66) E. Samara, M. Bialer and D.J. Harvey: Identification of glucose conjugates as major urinary metabolites of cannibidiol in the dog. Xenobiotica 20:177-183 (1990).
 * 67) E. Samara, M. Bialer, H. Bar-On and D.J. Harvey: Identification of metabolites of the 1", 1" dimethylheptyl analogue of cannabidiol in rat and dog in vivo.  Xenobiotica 20:447-455 (1990).
 * 68) E. Samara, M. Bialer and D.J. Harvey: Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm. Drug Disposit. 11:785-795 (1990).
 * 69) A.G. McLean, D.A. Ruggirello, C. Banfield, M.A. Gonzalez and M. Bialer: Application of a variance-stabilizing transformation approach to linear regression of calibration lines. J. Pharm. Sci. 79:1005-1008 (1990).
 * 70) M. Bialer: Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20:114-122 (1991).
 * 71) K. Badir, A. Haj-Yehia, T.B. Vree, E. van der Kleijn and M. Bialer:  Pharmacokinetics and anticonvulsant activity of three mono-esteric prodrugs of valproic acid. Pharm. Res. 8:750-753 (1991).
 * 72) A. McLean, E.A. Cefali, J.S. Roden, M.A. Gonzalez and M. Bialer: Stability studies of diltiazem in different biological fluids. Biopharm. Drug Disposit. 12:327-334 (1991).
 * 73) C.J. Betlach, A.B. Straughn, M.C. Meyer, M. Bialer, V.I. Vashi, P. Lieberman and M.A. Gonzalez: The effect of raising gastric pH with ranitidine on the absorption and elimination of theophylline from a sustained-release theophylline tablet. Pharm. Res. 8:1516-1519 (1991).
 * 74) E. Samara, M. Bialer and D.J. Harvey: Metabolism of cannabidiol by the rat. Eur. J. Drug Metab. Pharmacokinet. 16:305-313 (1991).
 * 75) M. Bialer: Prodrugs of valproic acid. Trends in Medicinal Chemistry '90, S. Sarel, R. Mechoulam and I. Agranat (Eds.), IUPAC/Blackwell, London, (1992), pp.377-382.
 * 76) M. Bialer: Pharmacokinetic evaluation of sustained-release formulations of antiepileptic drugs. Clin. Pharmacokinet. 22:11-21 (1992).
 * 77) S. Hadad, T.B. Vree, E. van der Kleijn and M. Bialer: Pharmacokinetic analysis of esteric prodrugs of valproic acid. J. Pharm. Sci. 81:1047-1050 (1992).
 * 78) A. Haj-Yehia, S. Hadad and M Bialer: Pharmacokinetic evaluation of the structural requirements for a stable valpromide analog. Pharm. Res. 9:1058-1063 (1992).
 * 79) S. Hadad, T.B.Vree, E. van der Kleijn and M. Bialer: Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid. Biopharm. Drug. Disposit. 14:51-59 (1993).
 * 80) A.A. Gabizon, Y. Barenholz and M. Bialer: Prolongation of the circulation of doxorubicin encapsulated in liposomes containing a polyethylene glycol - derivatized phospholipid. Pharmacokinetic studies in rodents and dogs. Pharm. Res. 10:703-708 (1993).
 * 81) B. Yagen and M. Bialer: Metabolism and pharmacokinetics of T-2 toxin and related trichotecenes. Drug Metab. Rev. 25:281-323 (1993).
 * 82) M. Bialer: Comparative pharmacokinetics of the newer antiepileptic drugs. Clin. Pharmacokinet. 24:441-454 (1993).
 * 83) F. Pisani, A. Haj Yehia, F. Fazio, C.Artesi, G. Oteri, E. Perucca, D.L. Kroetz, R.H. Levy and M. Bialer: Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia. 34:954-959 (1993).
 * 84) M. Bialer, S. Hadad, G. Golomb, S. Barel, E. Samara, O. Abu Salach, N. Berkman, H.D. Danenberg, J. Ben David, D. Caron, R. Kaplan, A. Tamir and M. Friedman: Pharmacokinetic analysis of two new sustained release products of  diltiazem designed for twice and once daily treatment. Biopharm. Drug Disposit. 15:45-52 (1994).
 * 85) M. Bialer, A. Haj Yehia, K. Badir and S. Hadad: Can we develop improved derivatives of valproic acid? Pharm. World Sci. 16:2-6 (1994).
 * 86) M. Bialer, Z. Plaraj, S. Zuckerman, I. Raz, O. Abramsky, J. Sterling and D. Ladkani: Pharmacokinetic analysis of valdice - a diethylcarbonate prodrug of valproic acid. Eur. J. Pharm. Sci. 2:239-244 (1994).
 * 87) O. Abu Salach, S. Hadad, A. Haj-Yehia, S. Sussan and M. Bialer: Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity. Pharm. Res. 11:1429-1434 (1994).
 * 88) S. Barel, B. Yagen and M. Bialer: Pharmacokinetics of conjugated verrucarol metabolites in dogs. Biopharm. Drug Disposit. 15:609-616 (1994).
 * 89) S. Soback, M. Gips, M. Bialer and A. Bor: The effect of lactation on single dose pharmacokinetics of norfloxacin nicotinate in ewes. Antimicrob. Agent Chemother. 38:2336-2339 (1994).
 * 90) E. Perucca, S. Barel, S. Soback, M. Gips, E. Spira and M. Bialer: The inhibition of diazepam by fluvoxamine: A pharmacokinetic study in normal subjects. Clin. Pharmacol. Ther. 56:471-476 (1994).
 * 91) M. Bialer and J.C. Cloyd: General principles: Formulations and routes of administration. In: Antiepileptic Drugs, Fourth Edition, R.H. Levy, R.H. Mattson, B.S. Meldrum (Eds), Raven Press, New York, U.S.A. (1995) pp. 161-178.
 * 92) F. Pisani and M. Bialer: Ethosuximide: Chemistry and biotransformation. In: Antiepileptic Drugs, Fourth Edition, R.H. Levy, R.H. Mattson and B.S. Meldrum (Eds.), Raven Press, New York, U.S.A. (1995) pp. 654-658.
 * 93) M. Bialer, S. Xiaodong and E. Perucca: Ethosuximide: Absorption, distribution and excretion. In: Antiepileptic Drugs, Fourth Edition, R.H. Levy, R.H. Mattson and B.S. Meldrum (Eds), Raven Press, New York, U.S.A. (1995) pp. 659-665.
 * 94) E. Samara, D. Avnir, D. Ladkani and M. Bialer: Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharm. Drug Disposit. 16:201-210 (1995).
 * 95) S. Hadad and M. Bialer: Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. Pharm. Res. 12:905-910 (1995).
 * 96) M. Bialer, S. Sussan, O. Abu Salach, H.D. Danenberg, J. Ben David, Y. Gibor and A. Laor: Criteria to assess in vivoperformance of sustained release products: Application to diltiazem formulations. J. Pharm. Sci. 84:1160-1163 (1995).
 * 97) J.P. Stables, M. Bialer, S.I. Johannessen, H.J. Kupferberg, R.H. Levy, P. Loiseau and E. Perucca: Progress report on new antiepileptic drugs: A summary of the Second Eilat Conference. Epilepsy Res. 22:235-246 (1995).
 * 98) M. Bialer, S. Hadad, B. Kadry, A. Abdul-Hai, A. Haj Yehia, J. Sterling, Y. Herzig and B. Yagen: Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropyl analogues of valpromide. Pharm. Res. 13:284-289 (1996).
 * 99) M. Bialer, B. Kadry, A. Abdul-Hai, A. Haj-Yehia, J. Sterling, Y. Hertzig and M. Shirvan: Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. Biopharm. Drug Disposit. 17:565-570 (1996).
 * 100) S. Blotnik, F. Bergman and M. Bialer: The disposition of valpromide, valproic acid and valnoctamide in brain, liver, plasma and urine of rats. Drug Metab. Disposit. 24:560-564 (1996).
 * 101) E. Perucca, M. Bialer: The clinical pharmacokinetics of the newer antiepileptic drugs. Clin. Pharmacokinet. 31:29-46 (1996).
 * 102) M. Bialer, S.I. Johannessen, H.J. Kupferberg, R.H. Levy, P. Loiseau and E. Perucca: Progress report on new antiepileptic drugs. A summary of the Third Eilat Conference. Epilepsy Res. 25:299-319 (1996).
 * 103) S. Barel, B. Yagen, V. Schurig, S. Soback. F. Pisani, E. Perucca and M. Bialer: Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and epileptic patients. Clin. Pharmacol. Ther. 61:442-449 (1997).
 * 104) M. Levi, B. Yagen and M. Bialer: Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Pharm. Res. 14:213-217 (1997).
 * 105) S. Blotnik, F. Bergman and M. Bialer: The disposition of valproyl glycinamide and valproyl glycine in rats. Pharm. Res. 14:873-878 (1997).
 * 106) S. Hadad and M. Bialer: Pharmacokinetic analysis and antiepileptic activity of two isomers of N-valproyl glycinamide. Biopharm. Drug Disposit. 18:557-566 (1997).
 * 107) O. Speigelstein, M. Bialer and B. Yagen: Isolation of N,N-dialkylated derivatives of valproyl glycinamide from dog plasma by active charcoal adsorption and their quantification by HPLC. J. Chromatog. Biomed. Applic. 698:195-200 (1997).
 * 108) M. Bialer, R.H. Levy and E. Perucca: Does carbamazepine have a narrow therapeutic plasma concentration range? Ther. Drug Monit. 20:56-59 (1998).
 * 109) S. Blotnik, F. Bergman and M. Bialer: Disposition of tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. Eur. J. Pharm. Sci. 6:93-98 (1998).
 * 110) M. Bialer, A. Yacobi, D. Moros, B. Levitt, J-M. Houle and M.S. Munsaka: Criteria to assess in vivo performance and bioequivalence of generic controlled release (CR) formultions of carbamazepine. Epilepsia 39:513-519 (1998).
 * 111) M. Radatz, K. Ehlers, B. Yagen, M. Bialer and H. Nau: Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res. 30:41-48 (1998).
 * 112) M. Bialer, L. Aracvi, S. Sussan, A. Volosov, A. Yacobi, D. Moros, B. Levitt and A. Laor: Existing and new criteria for bioequivalence evaluation of controlled release (CR) products of carbamazepine. Epilepsy Res. 32:371-378 (1998).
 * 113) A. Volosov and M. Bialer: Use of mean residence time to determine the magnitude of difference between rate constants and to calculate tmax in the Bateman Equation. Biopharm. Drug Disposit. 20:3-9 (1999).
 * 114) S. Sussan, A. Dagan and M. Bialer: Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives. Epilepsy Res. 33:11-21 (1999).
 * 115) M. Bialer, S.J. Johannessen, H.J. Kupferberg, R.H. Levy, P. Loiseau and E. Perucca: Progess report on new antiepileptic drugs: a summary of the Fourth Eilat Conference (Eilat IV). Epilepsy Res. 34:1-41 (1999).
 * 116) S. Sussan, A. Dagan, S. Blotnik and M. Bialer: Structural requirements for the design of antiepileptic-glycine derivatives. Epilepsy Res. 34:207-220 (1999).
 * 117) O. Spiegelstein, B. Yagen and M. Bialer: Structure-pharmacokinetic-pharmaco-kinetic relationships of the new antiepileptic drug valproyl glycinamide. Epilepsia 40:545-552 (1999).
 * 118) A. Volosov, A. Sintov and M. Bialer: Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxy carbazepine in dogs. Ther. Drug Monit.21:219-223 (1999).
 * 119) M. Roeder, V. Schurig, O. Spiegelstein, M. Bialer and B. Yagen: Absolute configuration of the four stereoisomers of valnoctamide (2-ethyl-3-methyl valeramide), a potential new stereospecific antiepileptic and CNS drug. Tetrahedron: Asymmetr.10:841-853 (1999).
 * 120) O. Spiegelstein, B. Yagen, R.H. Levy, R.H. Finnell, G.D. Bennett, M. Roeder, V. Schurig and M. Bialer: Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide - a CNS-active chiral amide of valproic acid. Pharm. Res. 16:1582-1588 (1999).
 * 121) O. Spiegelstein, M. Bialer, M. Radatz, H. Nau and B. Yagen: Asymmetric synthesis and teratogenicity of propylisopropyl acetamide - A CNS-active chiral amide analogue of valproic acid. Chirality 11:645-650, (1999).
 * 122) M. Bialer: Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J. Control. Release 62:187-192 (1999).
 * 123) A. Volosov, S. Xiandong, E. Perucca, B. Yagen, A. Sintov and M. Bialer: Enantioselective pharmacokinetics of 10-hydroxy carbazepine following oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol. Ther. 66:547-553 (1999).
 * 124) O. Spiegelstein, D.L. Kroetz, R.H. Levy, B. Yagen, S.I. Hurst, M. Levi, A. Haj-Yehia and M. Bialer: Structure activity relationships of human microsomal epoxide hydroalse inhibition by amide and acid analogues of valproic acid. Pharm. Res. 17:216-221 (2000).
 * 125) A. Volosov, M. Bialer, S. Xiandong, E, Perucca, A. Sintov and B. Yagen: Simultaneous stereoselective high performance liquid chromatograhic determination of 10-hydroxycarbazepine and its metabolite carbamzepine-10,11,-trans dihydrodiol in human urine. J. Chromatog. B. 738:419-425 (2000).
 * 126) M. Britizi, M. Bialer, J. Kapitulnik, L. Arcavi, H. Scacbri and S. Soback: Genetic polymorphism of CYP2D6 and CYP2C19 in ethnic groups in Israel. Ther. Drug Monit. 22:510-516 (2000).
 * 127) O. Spiegelstein, B. Yagen, G.D. Bennet, A. Finnell, S. Blotnik and M. Bialer: Stereoselective pharmacokinetic analysis of valnoctamide - a CNS-active chiral amide analogue of valproic acid in dogs, rats and mice. Ther. Drug Monit. 22:574-581 (2000).
 * 128) N. Isoherranen, M. Roeder, S. Soback, B. Yagen, V. Schurig and M. Bialer: Enantioselective analysis of levetiracetam and its enantiomer R--ethyl-2-oxo-pyrrolidine acetamide using gas chromatolography and ion trap mass spectrometric detection. J. Chromatog. B. 745:322-325 (2000).
 * 129) H. Lindekens, I. Smolders, G.M. Khan, M. Bialer, G. Ebinger and Y. Michotte. In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy. Pharm. Res. 17:1408-1413 (2000).
 * 130) A. Volosov, B. Yagen and M. Bialer: Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. Epilepsia 41:1107-1111 (2000).
 * 131) M. Bialer, S.J. Johannessen, H.J. Kupferberg, R.H. Levy, P. Loiseau and E. Perucca: Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 43:11-58 (2001).
 * 132) M. Wasserman, B. Yagen, S. Blotnik, N. Pappo and M. Bialer: Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a chiral central nerve system-active valproylamide. Ther. Drug Monit. 23:414-420 (2001).
 * 133) N. Isoherranen, B. Yagen, S. Soback, M. Roeder, V. Schurig and M. Bialer: Pharmacokinetic analysis of levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 42:825-830 (2001).
 * 134) N. Isoherranen, J.H. Woodhead, H.S. White and M. Bialer: Anticonvulsant profile of valrocemide (TV 1901): A new antiepileptic and CNS drug. Epilepsia 42:831-836 (2001).
 * 135) M. Bialer: New antiepileptic drugs currently in clinical trials. Is there a strategy in their development? Ther. Drug Monit. 24:85-90 (2002).
 * 136) N. Isoherranen, H.S. White, R.H. Finnell, B. Yagen, J.H. Woodhead, G.D. Bennett, K.S. Wilcox, M.E. Barton and M. Bialer: Anticonvulsant profile and teratogenicity of N-methyl tetramethylcyclopropyl carboxamide: A new antiepileptic drug. Epilepsia 43:115-126 (2002).
 * 137) R.C. Sachdeo, S.K. Sachdeo, R.H. Levy, A.J. Streeter, F.E. Bishop, K.L. Kunze, G.G. Mather, L.K. Roskos, D.D. Shen, K.E. Thummel, W.F. Trager, C.R. Curtin, D.R. Doose, L.G. Gisclon and M. Bialer: Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43:691-696 (2002).
 * 138) M. Bialer, M.C. Walker and J.W.A. Sander: Pros and cons for the development of new antiepileptic drugs. CNS Drugs 16:285-289 (2002).
 * 139) M. Bialer: Oxcarbazepine: Chemistry, biotransformation and pharmacokinetics. In: Antiepileptic Drugs, Fifth Edition, R.H. Levy, R.H. Mattson, B.S. Meldrum and E. Perucca (Eds), Lippincott, Philadelphia, U.S.A., 2002, pp. 459-465.
 * 140) F. Pisani, E. Perucca and M. Bialer: Succinimides: Chemistry, biotransformation, pharmacokinetics and drug interactions. In: Antiepileptic Drugs, Fifth Edition, R.H. Levy, R.H. Mattson, B.S. Meldrum and E. Perucca (Eds), Lippincott, Philadelphia, U.S.A., 2002, pp. 646-651.
 * 141) M. Bialer, S.J. Johannessen, H.J. Kupferberg, R.H. Levy, P. Loiseau and E. Perucca: Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51:31-71 (2002).
 * 142) J. Williams, M. Bialer, S.J. Johannessen, G. Kramer, R.H. Levy, R.H. Mattson, E. Perucca, P.N. Patsalos and J.F. Wilson: Interlabortory variability in the quantitation of new generation antiepileptic drugs based upon external quality assessment data. Epilepsia 44:40-45 (2003).
 * 143) S.J. Johannessen, D. Batino, D.J. Berry, M. Bialer, G. Kramer, T. Tomson and P.N. Patsalos: Therapeutics drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit.25:347-363 (2003).
 * 144) N. Isoherranen, B. Yagen, J.H. Woodhead, O. Spiegelstein, S. Blotnik,, K.S. Wilcox, , R.H. Finnell, G.D. Bennett, H.S. White and M. Bialer: Characterization of the anticonvulsant activity and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. Br. J. Pharmacol. 138:602-613 (2003).
 * 145) N. Isoherranen, B. Yagen, O. Spiegelstein, A. Steinman, R.H. Finnell and M. Bialer: Gas-chromatographic determination of novel valproyltaurinamide derivatives in mouse and dog plasma samples. J. Chromatog. B., 788:125-136 (2003).
 * 146) D.R. Doose, S-S. Wang, M. Padmanabhan, S. Schwabe, D. Jacobs and M. Bialer: Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and non-obese female subjects. Epilepsia, 44:540-549 (2003).
 * 147) N. Isoherranen, B. Yagen and M. Bialer: New CNS-active drugs which are second generation valproic acid: Can they lead to the development of the magic bullet? Curr. Opin. Neurol. 16:203-211 (2003).
 * 148) M. Britzi, S. Soback, N. Isoherranen, R.H. Levy, E. Perucca, D.R. Doose, B.E. Maryanoff and M. Bialer: Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass sepctrometry assay. Ther. Drug Monit.25:314-322 (2003).
 * 149) N. Isoherranen, H.S. White, B.D. Klein, M. Roeder, B. Yagen, J.H. Woodhead, V. Schurig and M. Bialer: Pharmacokinetic-pharmacodynamic relationships of 2S,3S-valnoctamide and its stereoisomer 2R,3S-valnoctamide in animal models for epilepsy. Pharm. Res.20:1293-1301 (2003).
 * 150) N. Isoherranen, B. Yagen, O. Spiegelstein, R.H. Finnell, M. Merriweather, J.H. Woodhead, B. Wlodarczxyk, H.S. White and M. Bialer: Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. Brit. J. Pharmacol.139:755-764 (2003).
 * 151) D.R. Doose, M.J. Brodie, E. Wilson, D. Chadwick, J. Oxbury, S. Schwabe and M. Bialer: Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 44:917-922 (2003).
 * 152) N. Isoherranen, O. Spiegelstein, M. Bialer, J. Zhang, M. Merriweather, B. Yagen, M. Roeder, A.A. Tripplett, V. Schurig and R.H. Finnell: Developmental outcome of levetiracetam, its major acid metabolite in humans (R)-α-ethyl-oxo-pyrrolidone 2-pyrrolidinone N-butyric acid and its enantiomer in a mouse model of antiepileptic drug teratogenicity. Epilepsia 44:1280-1288 (2003).
 * 153) E. Sobol and M. Bialer: Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (Vss) utilizing a model-independent approach. Biopharm. Drug Disposit., 25:99-101(2004).
 * 154) A. Okada, H. Kurithara, Y. Aoki, M. Bialer and M. Fujiwara: Amidic modification of valproic acid reduces skeletal teratogenicity in mice. Birth Defect. Res. (Part B), 71:47-53 (2004).
 * 155) N. Isoherranen, R.H. Levy, B. Yagen, J.H. Woodhead, H.S. White and M. Bialer: Metabolism of a new antiepileptic drug, N-methyl cyclopropane carboxamide, and anticonvulsant activity of its metabolites. Epilepsy Res.58:1-12 (2004).
 * 156) M. Bialer, D.R. Doose, B. Murthy, C. Curtin, S-S Wang, R.E. Twyman and S. Schwabe: Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43:763-780 (2004).
 * 157) E. Sobol and M. Bialer: The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model. Biopharm. Drug Disposit. 25:157-162 (2004).
 * 158) S. Eyal, B. Yagen, E. Sobol, Y. Altschuler, M. Shmuel and M. Bialer: The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45:737-744 (2004).
 * 159) E. Sobol. M. Bialer and B. Yagen. Tetramethylcyclopropyl analogue of a leading antiepileptic drug-valproic acid. Synthesis and evaluation of the anticonvulsant activity of its amide derivatives. J. Med. Chem. 47:4316-4326 (2004).
 * 160) M. Bialer, S.J. Johannessen, H.J. Kupferberg, R.H. Levy, E. Perucca and T. Tomson: Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61:1-48 (2004).
 * 161) M. Bialer, R. E. Twyman and H. S. White. Correlation analysis between anticonvulsant-ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy & Behavior 5:866-872 (2004).
 * 162) A. Okada, Y. Aoki, K. Kushima, H. Kurithara, M. Bialer and M. Fujiwara: Plycopmb homologues are involved in teratogenicity of valproic acid in mice. Birth Defect. Res (Part A) 70:870-879 (2004).
 * 163) G. Shaltiel, A. Shamir, J. Shapiro, D. Ding, E. Dalton, M. Bialer, A.J. Harwood, R.H. Belmaker, M.L. Greenberg and G. Agam: Valpraote decreases inositol biosynthesis. Biol. Psychiatr. 56:868-874 (2004).
 * 164) E. Sobol and M. Bialer. Critical analysis of the discrepancy between Vß and Vss for drugs exhibiting different two-compartment disposition profiles. Biopharm. Drug Disposit.26:51-58 (2005).
 * 165) M. Britzi, E. Perucca, S. Soback, R. H. Levy, C. Fattroe, F. Crema, G. Gatti, D. R. Doose, B. E. Maryanoff and M. Bialer. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in presence and absence of enzyme induction by carbamazepine. Epilepsia 46:378-384 (2005).
 * 166) R. P. Shank, D.R. Doose, A. J. Streeter and M. Bialer. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res. 63:103-112 (2005).
 * 167) A. Okada, K. Kushima, Y. Aoki, H. Kurihara, M. Bialer and M. Fujiwara. Identification of early responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defect. Res. (Part A) 73:229-238 (2005).
 * 168) S. Eyal, B. Yagen, J. Shimshoni, and M. Bialer. Hositone deacetylase inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem. Pharmacol. 69:1501-1508 (2005).
 * 169) D. Mimrod, L.M. Specchio, M. Britzi, E. Perucca, N. Specchio, A. La Neve, S. Soback, R. H. Levy, G. Gatti, D.R. Doose, B.E. Maryanoff and M. Bialer. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady-state in patients with epilepsy. Epilepsia 46:1046-1054 (2005).
 * 170) I. Winkler, S. Blotnik, J. Shimshoni, B. Yagen, M. Devor and M. Bialer. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Brit. J. Pharmacol.146:198-208 (2005).
 * 171) I. Winkler, E. Sobol, B. Yagen, A. Steinman, M. Devor and M. Bialer. Efficacy of antiepileptic tetramethylcyclopropyl analogs of valproic acid amides in a rat model for neuropathic pain. Neuropharmacology 49:1110-1120 (2005).
 * 172) E. Sobol, B. Yagen, I. Winkler, M. Britzi, D. Gibson and M. Bialer. Pharmacokinetics and metabolism of a new potent anticonvulsant agent, 2,2,3,3-tetramethylcyclopropylcarbonylurea in rats. Drug Metab. Disposit. 33:1538-1546 (2005).
 * 173) M. Bialer. The pharmacokinetics and interactions of new antiepileptic drugs (AEDs): An overview. Ther. Drug Monit. 27: 722-726 (2005).
 * 174) M. Bialer. New antiepileptic drugs (AEDs) in clinical development which are second generation to existing AEDs. Expert Opin. Invest. Drug. 15:637-647 (2006).
 * 175) A. Okada, Y. Onishi, Y. Aoki, K. B. Yagen, E. Sobol, M. Bialer and M. Fujiwara: Teratology studies of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defect. Res. (Part B) 77:227-233 (2006).
 * 176) S. Eyal, J. G. Lamb, M. Smith-Yockman, B. Yagen, E. Fibach, Y. Altschuler, H. S. White and M. Bialer: The antiepileptic and chemotherapeutic agent valproic acid induces P-glycoprotein in human tumor cell lines and in rat liver. Brit. J. Pharmacol. 149:250-260 (2006).
 * 177) E. Sobol, B. Yagen, H. S. White, K. S. Wilcox, J. G. Lamb, O. Pappo, B. Wlodarczyk, R.H. Finnell and M. Bialer. Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonylurea, a novel second generation to valproic acid, antiepileptic drug. Neuropharmacology 51:933-946 (2006).
 * 178) C. Yao, S. Chien, D. R. Doose, J. Novak and M. Bialer. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369, following single and multiple doing to humans. Epilepsia 47:1822-1829 (2006).
 * 179) S. Chien, M. Bialer, B. Solanki, T. Veraeghe, D. R. Doose, J. Novak and C. Yao. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy subjects. Epilepsia 47:1830-1840 (2006).
 * 180) G. S. J. Mannens, J. Henrdickx, C.G.M. Janssen, S. Chein, B.  Van Hoof, T. Vergaeghe, M. Kao, M. F Kelley, I. Goris, M. Goris, M. Bockx, B. Verreet, M. Bialer and W. Meuldermans. The absorption, metabolism and excretion of the novel neuromudulator RWJ-333369, (1,2-ethandiol, [1,2-chlorophenyl]-2-carbamate, [S]-) in humans. Drug Metab. Disposit.35:554-565 (2007).
 * 181) E. Sobol, B. Yagen, J. G. Lamb, H. S. White, B. Wlodarczyk, R.H. Finnell and M. Bialer. Anticonvulsant activity, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropanecarbxamide. Epilepsy Res. 73:75-84 (2007).
 * 182) M. Bialer, B. Yagen.  Valproic acid – Second generation. Neurotherapeutics, 4:130-137 (2007).
 * 183) M. Bialer, S.J. Johannessen, H.J. Kupferberg, R.H. Levy, E. Perucca and T. Tomson: Progress report on new antiepileptic drugs: A summary of the Eight Eilat Conference (EILAT VIII). Epilepsy Res.73:1-52 (2007).
 * 184) T. Glauser, M. Bialer. Rufinamide. In: Epilepsy: A Comprehensive Textbook, T. Pedley and J. Engel (eds). 2nd edit, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 2007, pp.1647-1654 2007, pp.1647-1654.
 * 185) C. Elger, M. Bialer, J. A. Cramer, J. Maia, L. Almeida and P. Soares-da-Silva. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48: 497-504 (2007).
 * 186) J. Shimshoni, E. C. Dalton, A. Jenkins, S. Eyal, K. Ewen, R. S. B. Williams, N. Pessah, B. Yagen, J. A. Harwood and M. Bialer. The effect of CNS-active valproic acid constitutional isomers, cyclopropyl analogues and amide derivatives on neuronal growth cone behavior. Mol. Pharmacol. 71:884-892 (2007).
 * 187) S. Chien, C. Yao, A. Mertens, T. Veraeghe, B. Solanki, D. R. Doose, G. Novak and M. Bialer. A pharmacokinetic interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Epilepsia 48:1328-1338 (2007).
 * 188) M. Bialer. Extended release formulations for the treatment of epilepsy. CNS Drugs 21:765-774 (2007).
 * 189) E. Perucca, J. French and M. Bialer. Developing novel antiepileptic drugs (AEDs): Challenges, incentives and recent advances. Lancet Neurol., 6:793-804 (2007).
 * 190) M. Bialer. Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia, 48:1825-1832 (2007).
 * 191) M. Bialer. Clinical pharmacology of parenteral use of antiepileptic drugs. Epilepsia, 48 (Suppl. 8): 46-48 (2007).
 * 192) J. A.  Shmishoni, M. Bialer, B. Wlodarczyk, R. H. Finnell and B. Yagen. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J. Med. Chem. 50: 6419-6427 (2007).
 * 193) D. Kaufmann, B. Yagen, A. Minert, M. Tal, M. Devor and M. Bialer. Evaluation of the enantioselective antiallodynic profile and pharmacokinetics of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacology 54:699-707 (2008).
 * 194) J. Shmishoni, M Bialer and B. Yagen. Synthesis and anticonvulsant activity of new tetramethylcyclpopropylcarboaxamide aromatic derivatives. Bioorg. Med. Chem.16:6297-6305 (2008).
 * 195) J A. Shmishoni, B. Yagen, N. Pessah, B. Wlodarczyk, R. H. Finnell and M. Bialer. Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: A potential for a second generation drug to valproic acid. Epilepsia 49: 1202-1212 (2008).
 * 196) A. Okada, Y. Onishi, B. Yagen, J. A. Shimshoni, D. Kaufamnn, M. Bialer and M. Fujiwara: Tetratmethylcyclopropyl analogues of the leading antiepileptic drug, valproic acid, evaluation of the teratogenic effects of its amide derivatives in NMRI mice. Birth Defect Research (Part A) 82: 610-621 (2008).
 * 197) P. Soares-da-Silva,  L. Almeida, M. Bialer: Eslicarbazepine Acetate. In: The Treatment of Epilepsy, S. Shorvon, E. Perucca and J. Engel (eds). 3rd edit, Wiley-Blackwell, Oxford, UK, 2009, pp.485-498.
 * 198) M. Bialer, S.J. Johannessen, R.H. Levy, E. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 83:1-43 (2009).
 * 199) P. Zannikos, G. Novak, C. Yao, T. Veraeghe, B. Solanki, M. A. Franc and M. Bialer. Pharmacokinetic of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. Epilepsia 50:1850-1859 (2009).
 * 200) J. Shimshoni, E. C. Dalton, K. Ewen, B.Yagen, M. Bialer and A. J. Harwood. Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology. Neuropharmacology 56:831-837 (2009).
 * 201) N. Pessah, M. Bialer, B. Wlodarczyk, R. H. Finnell and B. Yagen, a-Fluoro-2,2,3,3-teteramethylcylcopropanecarboaxamide a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J. Med. Chem. 52:2233-2242 (2009).
 * 202) M. Bialer. Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus. Epilepsia 50 (Suppl.12): 44-48 (2009).
 * 203) A. Okada, H. Noyori, B. Yagen, J. A. Shimshoni, M. Bialer and M. Fujiwara: Teratogenic evaluation of new potent analogues of a valproic acid derivative in NMRI mice. Birth Defect Research (Part B), 83:1-8 (2009).
 * 204) D. Kaufmann, M. Bialer, A. Shimshoni, M. Devor and B. Yagen. Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. J. Med. Chem., 52: 7236-7248 (2009).
 * 205) M. Bialer, H. S. White. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nature Rev. Drug Discov. 9: 68-83 (2010).
 * 206) J. A. Shimshoni, B. Yagen, B. Wlodarczyk, R. H. Finnell, V. Schurig and M. Bialer. Evaluation of stereoselective, anticonvulsant, teratogenic and pharmacokinetic profile of valnoctylurea (capuride): A chiral stereoisomer of valproic acid urea derivative. Epilepsia, 51: 323-332 (2010)
 * 207) M. Bialer, K. K. Midha. Generic products of antiepileptic drugs (AEDs): A perspective on bioequivalence and inter changeability. Epilepsia, 51: 941-950 (2010).
 * 208) D. Kaufmann, B. Yagen, A. Minert, B. Wlodarczyk, R. H. Finnell, V. Schurig, M. Devor and M. Bialer. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology, 52: 1228-1236 (2010).
 * 209) N. Hen, M. Bialer, B. Wlodarczyk, R.H. Finnell B. Yagen. Synthesis and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-main-benzenesuklfonamide. J. Med. Chem., 53: 4177-4186 (2010).
 * 210) N. Pessah, B. Yagen, D.  Kaufmann, B. Wlodarczyk, R.H. Finnell, M. Bialer. Comparative pharmacokinetic and pharmacodynamic analysis of two anticonvulsant halo-amide derivative of a cyclic analogue of valproic acid. Epilepsia, 61: 1944-1953 (2010).
 * 211) M. Bialer, S.J. Johannessen, R.H. Levy, E. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the tenth Eilat Conference (EILAT X). Epilepsy Res.92:89-124 (2010).
 * 212) N. Hen, M. Bialer, B. Yagen, A. Maresca, M. Aggarwal, A. H. Robbins, R. McKenna, A. Scozzafava, C. T. Supuran... Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII and XIV. J. Med. Chem. 54:3977-3981 (2011).
 * 213) L. J. Lmabert, T. Shekh-Ahmed, W. M. Todd, M. B. Halvorsen, M. Bialer. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia, 52:1877-1883 (2011).
 * 214) N. Pessah, B. Yagen, N. Hen, J. A. Shimshoni, B. Wlodarczyk, R.H. Finnell, M. Bialer. Design and pharmacological activity of glycinamide and N-methoxy-amide derivatives of analogues and constitutional isomers of valproic acid. Epilepsy Behav.22:461-468 (2011).
 * 215) P. Chang, B. Orabi, R.M. Deranieh, M. Dham, O. Hoeller, J. A. Shimshoni, B. Yagen, M. Bialer, M. J. Greenberg, M. C. Walker, R. S. B. Williams. The antiepileptic drug valproic acid and other medium chain fatty acids acutely reduce phosphoinositidie levels independently of imposition in Dictyostelium. Dis. Model. Mech.5:115-124 (2012).
 * 216) T. Shekh-Ahmad, M. Bialer, E. Yavin. Synthesis and anticonvulsant evaluation of diethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. Epilepsy Res.98: 238-246 (2012).
 * 217) H. S. White, A. B. Alex, A. Pollock, N. Hen, T. Shekh-Ahmed, K. S. Wilcox, J. H. McDonough, J. P. Stables, D. Kaufmann, B. Yagen, B. Bialer. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 53:134-146 (2012)
 * 218) M. Bialer. Chemical properties of antiepileptic drugs (AEDs). Adv. Drug Deliv. Rev. 64: 887-895 (2012)
 * 219) I. Bejarano-Achache, L. Levy, L. Mlynarsky, M. Bialer, M. Muszkat, Y. Caraco. The impact of CYP4F2 genetic polymorphism on warfarin responsiveness during initiation phase. A prospective, open-label, observational, cohort study. Clin. Ther. 34: 811-823 (2012).
 * 220) N. Hen, M. Bialer, B. Yagen. Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. J. Med. Chem. 55:2835-2845 (2012).
 * 221) M. Bialer, P. Soares-da-Silva. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia.53: 935-946 (2012).
 * 222) P. E. M. Smith, M. Bialer. Introduction to: The borderline of epilepsy. Epilepsia 53 (suppl. 7): 1-2 (2012).
 * 223) M. Bialer. Why are antiepileptic drugs (AEDs) are used for non-epileptic conditions? Epilepsia, 53 (suppl. 7): 26-33 (2012).
 * 224) M. Bialer, P. E. M. Smith. Introduction to: Phenobarbital: The centenary. Epilepsia 53 (suppl. 8): 1-2 (2012).
 * 225) M. Bialer. How Phenobarbital chemical Structure Affected the Development of Subsequent Antiepileptic Drugs (AEDs)? Epilepsia, 53 (suppl. 8): 3-11 (2012).
 * 226) M. Bialer, S.J. Johannessen, R.H. Levy, E. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the eleventh Eilat Conference (EILAT XI). Epilepsy Res., 103: 2-30 (2013).
 * 227) W. Pouliot, M. Bialer, N. Hen, T. Shekh-Ahmad, D. Kaufmann, B. Yagen, K. Ricks, B. Roach, C. Nelson, F.  E. Dudek. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 231:145-156 (2013)
 * 228) M. Bialer, T. Shekh-Ahmed, T.E. Braun. M. B. Halvorsen. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 54:1444-1451 (2013).
 * 229) H.R. Modi, M. Basselin, A.Y. Taha, L.O. Li, R.A. Coleman, M. Bialer, S. I. T Rapport. Propylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-Co synthethase 4: A potential drug for bipolar disorder. Biochem. Biophys. Acta 1831:880--886 (2013).
 * 230) T. Shekh-Ahmad, N. Hen, J. H. McDonough, B. Yagen, M. Bialer. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia., 54 (Suppl 5):98-101 (2013).
 * 231) C. Elger, M. Bialer, A. Falcão, M. Vaz-da-Silva, T. Nunes, L. Almeida, P. Soares-da- Silva.Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy subjects. Epilepsia 54:1453-1461 (2013).
 * 232) P. Mareš, H. Kubová, N. Hen, B. Yagen, M. Bialer Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. Epilepsy Res106:64-72 (2013)
 * 233) Y. Onishi, A. Okada, H. Noyori, A. Okamura, N. Hen, B. Yagen, M. Bialer, M. Fujiwara: Teratology study of amide derivatives of branched aliphatic carboxylic acid with 4-aminobenzensulfonamoide in NMRI mice. Birth Defect Research (Part B) 98:318-327 (2013).
 * 234) M. G. Neuman, R. M. Manu, T. Shekh-Ahmad, B. Yagen, M. Bialer. Valproic acid derivatives signal for apoptosis and repair in vitro. Clin. Biochem., 46: 1532-1537 (2013).
 * 235) N. Hen, T. Shekh-Ahmad, B. Yagen, J. H. McDonough, R. H. Finnell, B. Wlodarzyk, M. Bialer. Stereoselective pharmacoydnamic and pharmacokinetic analysis of sec-propyl-butylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J. Med. Chem.56:6467-6477 (2013).
 * 236) V. Karalis, M. Bilaer, P. Macheras. Quantitiatve assessment of the swaitcahblity of generic products. Eur. J. Pharm. Sci 50:476-483 (2013).
 * 237) V. Karalis, P. Macheras, M. Bialer. Generic products of aniepileptic drugs: A perspective on bioequivalence, bioavailability and galenic versus generic formulation switches using Monte Carlo simulations. CNS Drugs, 28:69-77 (2014).
 * 238) T. Shekh-Ahmad, N. Hen, B. Yagen, J. H. McDonough, R. H. Finnell, B. Wlodarczyk, M. Bialer. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a non-teratogenic CNS-active derivative of valproic acid with potential in epilepsy, bipolar disorder and neuropathic pain. Epilepsia 55:353-361 (2014).
 * 239) T. Shekh-Ahmad, H. Mawasi, J. H. McDonough, R. H. Finnell, B. J. Wlodarczyk, E. Yavin, M. Bialer. Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. Epilepsia 55:1944-1952 (2014)
 * 240) G. Bar-Klein, E. Swissa, L. Kamintsky, T. Shekh-Ahmad, Y. Hubary, S. Shrot, L. Stetlander, A. Eisenkraft, A. Friedman, M. Bialer . Sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia, 55: 1953-1958 (2014)
 * 241) M. Bialer, C. Elger: Eslicarbazepine Acetate. In: The Treatment of Epilepsy, S. Shorvon, E. Perucca and J. Engel (eds). 4th edit, Wiley-Blackwell, Oxford, UK, 2015, pp. 447-459.
 * 242) M. Bialer, S.J. Johannessen, R.H. Levy, E. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 111: 85-141 (2015).
 * 243) H. Mawasi, T. Shekh-Ahmad, R. H. Finnell, B. J. Wlodarczyk M. Bialer. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide (SPD) - amide derivatives of valproic acid. Epilepsy Behav., 15 :72-78 (2015)
 * 244) T. Shekh-Ahmad, H. Mawasi, T. J.H. McDonough, B. Yagen, M. Bialer. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav.15:298-302 (2015).
 * 245) B. J. Wlodarczyk, K. Ogle, L. Ying Lin, M. Bialer, R.H. Finnell. Comparative teratogenicity analysis of valnoctamide, risperidone and olanzapine in mice. Bipolar Disorder, 17: 615-625 (2015).
 * 246) A. D Korczyn, J. Amlerova, M. Bialer,W. van Emde Boas, M.Brázdil; E. Brodtkorb, J. Engel, J.Gotman,V. Komárek; I.E Leppik; P. Marusic, S. Meletti, B.Metternich;, C. Moulin, N. Muhlert, M. Mula; K.O Nakken, F. Picard,A. Schulze-Bonhage, W.T heodor,; P. Wolf; A. Zeman; I. Rektor. Third International Congress on Epilepsy, Brain and Mind: Part 1. Epilepsy Behav. 50: 116-137 (2015).
 * 247) D. Kaufmann, E. A. Bates, B. Yagen, M. Bialer, G. H. Saunders, K. Wilcox, H. S. White, K.C. Brennan. sec-Butylpropylacetamide (SPD) has antimigraine properties. Cephalagia, 36:924-935 (2016).
 * 248) H. Mawasi, D.  Bibi, T. Shekh-Ahmad, C. Shaul, S. Blotnick, M. Bialer.. Pharmacokinetic and pharmacodynamic analysis after various routes of administration of sec-butylpropylacetamide (SPD), a new CNS drug possessing a unique activity against status epilepticus. Mol. Pharmaceutic.13:2492-2496 (2016).
 * 249) H. Mawasi, D. Bibi, M. Bialer. Syntheses and Comparative Anticonvulsant Activity Assessment of CNS-Active Imidazole Derivatives. Bioorg. Med.Chem. 24:4246-4253 (2016).
 * 250) C. Shaul, S. Blotnick, M. Muszkat, M. Bialer, Y. Caraco. The Impact of CYP2C9 Genetic Polymorphism on the Oral Clearance of S-warfarin. Mol Diagnos. Ther, 21:75-83 (2017).
 * 251) D. Kaufmann, M. H. Slawson, P. J. West, M. D. Smith, B. Yagen, K.C. Brennan, M. Devor, M. Bialer, H. S. White. sec-Butylpropylacetamide (SPD) a new derivative of valproic acid for the treatment of neuropathic and inflammatory pain. Pharmacol. Res 17: 129-139 (2017).
 * 252) M. Bialer, S.J. Johannessen, R.H. Levy, E. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the Thirteen Eilat Conference (EILAT XIII). Epilepsia 58:181-221 (2017).
 * 253) M. Bialer, S.J. Johannessen, R.H. Levy, E. Perucca, T. Tomson, M.J. Koepp, H. S. White. Seizure detection and neuromodulation:  A summary of the Thirteen Eilat Conference on New antiepileptic and devices (EILAT XIII). Epilepsy Res.130: 27-36 (2017).
 * 254) A.P. Kudin, H. Mawasi, A. Eisenkraft, C.E. Elger, M. Bialer, W.S. Kunz. Mitochndrial liver toxicity of valproic acid and its acid derivatives is related to inhbition of alpha-lipoamide dehydrogensae. Int. J. Mol. 19: 1912-1923 (2017).
 * 255) D. Bibi, H. Mawasi, A. Nocentini, C. T. Supuran, B. Wlodarczyk, R.H. Finnell, M. Bialer. Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide . Neurochem. Res. 42: 1972-1982 (2017)
 * 256) M.  Weiser, L. Levi, S. Z Levine, M. Bialer, T. Shekh-Ahmad, V. Matei, A. Tiugan, D. Cirjaliu, C.Sava, F. Sinita, D. Zamora, J.M. Davis.. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disorder. 19: 285-294 (2017).
 * 257) M. Bialer, S.J. Johannessen, M. Koepp, R.H. Levy, E. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the fourteen Eilat Conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia 59: 1811-1841 (2018).
 * 258) M. Bialer, S.J. Johannessen, M. Koepp, R.H. Levy, E. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the fourteen Eilat Conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia 59: 1842-1855 (2018).
 * 259) L.L. Ying., M. Bialer, R.M. Cabrera, R.H. Finnell, B. J. Wlodarczyk Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. Birth Def. Res.92: 1-11 (2018).
 * 260) K. M. Haine, L. M. Matson, E. N. Dunn, C E. Ardinger, D. Bibi, J. H. McDonough, M. Bialer. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agents-induced seizures in pediatric rats. Epilepsia 60: 315-321 (2019).
 * 261) M. Bialer, S.J. Johannessen, R.H. Levy, E. Perucca, T. Tomson, M.J. Koepp, H. S. White. Virtual special issue “Neuromodulation”: A summary of the data presented at the XIV conference on new antiepileptic and devices (EILAT XIV). Epilepsy Res. 153:66-67 (2019).
 * 262) D. Bibi, B. Shusterman, A. Nocentini, C. T. Supuran, M. Bialer.. ,Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulfamoylphenyl carbamate derivative. J. Enzyme Inhibit. Med. Chem, 34:1078-1082 (2019).
 * 263) M. Bialer, U.B.S. Hedrich, L. Lagai, H. Lerche. Novel treatment approaches and pediatric research networks in status epilepticus. Epilepsy Behav.doi.org/10.1016/j.yebeh.2019.106564.
 * 264) D. Bibi, M. Bialer. Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs - A CNS-active stereoisomer of SPD. Epilepsia 61:149-156 (2020).
 * 265) M. Bialer, E. Perucca. Does Cannabidiol Have Antiseizure Activity Independent of its Interactions with Clobazam? An Appraisal of the Evidence from Randomized Controlled Trials. Epilepsia, 61: 1082-1089 (2020).
 * 266) E. Perucca, M. Bialer. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs, 34; 795-800 (2020).
 * 267) R. Odi, D. Bibi, T. Wager, M. Bialer. A Perspective into the physicochemical and biopharmaceutic properties of marketed antiepileptic drugs - from phenobarbital to cenobamate and beyond. Epilepsia, 61:1543-1552 (2020).
 * 268) M. Bialer, E. Perucca. Response: Cannabidiol antiseizure activity and its interactions with clobazam: “It’s déjà vu all over again” Yogi Berra. Epilepsia 61: 1793-1794 undefined (2020).
 * 269) V. Franco, P. Gershkovich, E. Perucca, M. Bialer. The interplay between liver first pass effect and lymphatic absorption of cannabidiol and its implications on cannabidiol oral formulations. Clin Pharmacokinet 59: 1493-1500 (2020).
 * 270) M. Bialer, S.J. Johannessen, M. Koepp, R.H. Levy, E. Perucca, P. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the fifteen Eilat Conference on new antiepileptic drugs and devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia 61: 2340–2364 (2020).
 * 271) M. Bialer, S.J. Johannessen, M. Koepp, R.H. Levy, E. Perucca, P. Perucca, T. Tomson, H. S. White: Progress report on new antiepileptic drugs: A summary of the fifteen Eilat Conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia 61: 2365–2385 (2020).
 * 272) R. Odi, V. Franco, E. Perucca, M. Bialer. A perspective on bioequivalence and switchability of generic AED products. Epilepsia 62: 285-302 (2021).
 * 273) V. Franco, M. Bialer, E. Perucca. Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research. Neruropharmacology, 185, 108442 (2021).
 * 274) R. Odi, D. Bibi, B. Shusterman, A. N. Erenburg, H. Shaul, Nocentini, C. T. Supuran, M. Bialer..Synthesis and enantioselective PK/PD analysis of new CNS-active sulfamoylphenyl carbamate derivative. Int. J. Mol Sci., 22, 3361 (2021).
 * 275) R. Odi, R.W. Invernizzi, T. Gallily, E. Perucca, M. Bialer. Fenfluramine repurposing from weight loss to epilepsy; what we do and do not know. Pharmacol Ther.226, 107866 (2021).
 * 276) M. Bilaer, E. Perucca. Lorcaserin for Dravet Syndrome- A potential advance over fenfluramine? CNS Drugs, in press.
 * 277) H. Shaul, S. Blotnick, L. Adar, M. Muszkat, M. Bialer, Y. Caraco. Phenytoin, via its metbalic ratio (PMR), as a probe for CYP2C9 activity. Submitted to Brit J. Clin. Pharmacol.

Article name is...